Review of once-monthly oral ibandronate and the use thereof
An advisory board meeting of key opinion leaders was held in 2015 to discuss the clinical data on oral ibandronate in the treatment of postmenopausal osteoporosis. Boniva 150 mg (ibandronate) oral once-monthly is indicated for the treatment of osteoporosis in postmenopausal women, in order to red...
Saved in:
| Main Authors: | T De Villiers, M Davey, B Cassim, W De Lange |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2017-08-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4728 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VIBE: Evaluation of Ibandronate Efficacy - Original Investigation
by: J-Y Reginster, et al.
Published: (2008-12-01) -
EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)
by: Evgeni Germanovich Zotkin
Published: (2010-06-01) -
The use of bisphosphonates for the treatment and prevention of osteoporosis
by: O. A. Nikitinskaya, et al.
Published: (2022-08-01) -
Safety of ilunocitinib tablets (Zenrelia™) after once daily oral administration in dogs
by: Emmanuelle A. Kuntz, et al.
Published: (2025-03-01) -
Intermittent intravenous ibandronate therapy for osteoporosis
by: L I Alekseeva, et al.
Published: (2008-09-01)